305 related articles for article (PubMed ID: 19339552)
21. Expression of the promyelocytic leukemia protein without the nuclear localization signal as a novel diagnostic marker for acute promyelocytic leukemia.
Xu T; Yang XQ; Jiang KL; Wang H; Ma PP; Zhong L; Liu BZ
Oncol Rep; 2017 Feb; 37(2):986-994. PubMed ID: 28075463
[TBL] [Abstract][Full Text] [Related]
22. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
23. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia.
Boddy MN; Howe K; Etkin LD; Solomon E; Freemont PS
Oncogene; 1996 Sep; 13(5):971-82. PubMed ID: 8806687
[TBL] [Abstract][Full Text] [Related]
24. Subcellular distribution of nuclear import-defective isoforms of the promyelocytic leukemia protein.
Jul-Larsen A; Grudic A; Bjerkvig R; Bøe SO
BMC Mol Biol; 2010 Nov; 11():89. PubMed ID: 21092142
[TBL] [Abstract][Full Text] [Related]
25. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein.
Shimada N; Shinagawa T; Ishii S
Genes Cells; 2008 Mar; 13(3):245-54. PubMed ID: 18298799
[TBL] [Abstract][Full Text] [Related]
26. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
27. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein.
Vallian S; Gäken JA; Gingold EB; Kouzarides T; Chang KS; Farzaneh F
Oncogene; 1998 Jun; 16(22):2843-53. PubMed ID: 9671405
[TBL] [Abstract][Full Text] [Related]
28. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
29. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
[TBL] [Abstract][Full Text] [Related]
30. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein.
Carbone R; Botrugno OA; Ronzoni S; Insinga A; Di Croce L; Pelicci PG; Minucci S
Mol Cell Biol; 2006 Feb; 26(4):1288-96. PubMed ID: 16449642
[TBL] [Abstract][Full Text] [Related]
31. [Research progress in cytoplasmic PML gene functions].
Xu XH; Sun YY; Zhang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):857-60. PubMed ID: 24989309
[TBL] [Abstract][Full Text] [Related]
32. Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.
Ho CL; Huang YC; Tai CK; Liu ST; Wang JK; Wang WM; Huang SM
Int J Biochem Cell Biol; 2010 Jun; 42(6):902-10. PubMed ID: 20097304
[TBL] [Abstract][Full Text] [Related]
33. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
34. The Oncogenic Fusion Proteins SET-Nup214 and Sequestosome-1 (SQSTM1)-Nup214 Form Dynamic Nuclear Bodies and Differentially Affect Nuclear Protein and Poly(A)+ RNA Export.
Port SA; Mendes A; Valkova C; Spillner C; Fahrenkrog B; Kaether C; Kehlenbach RH
J Biol Chem; 2016 Oct; 291(44):23068-23083. PubMed ID: 27613868
[TBL] [Abstract][Full Text] [Related]
35. A cytoplasmic PML mutant inhibits p53 function.
Bellodi C; Kindle K; Bernassola F; Cossarizza A; Dinsdale D; Melino G; Heery D; Salomoni P
Cell Cycle; 2006 Nov; 5(22):2688-92. PubMed ID: 17172828
[TBL] [Abstract][Full Text] [Related]
36. Dual roles for lysine 490 of promyelocytic leukemia protein in the transactivation of glucocorticoid receptor-interacting protein 1.
Liu ST; Lu GY; Hsu YJ; Chang LC; Ho CL; Huang SM
Biochim Biophys Acta; 2013 Aug; 1833(8):1799-810. PubMed ID: 23542129
[TBL] [Abstract][Full Text] [Related]
37. PML Bodies in Mitosis.
Lång A; Lång E; Bøe SO
Cells; 2019 Aug; 8(8):. PubMed ID: 31416160
[TBL] [Abstract][Full Text] [Related]
38. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells.
Yu J; Lan J; Wang C; Wu Q; Zhu Y; Lai X; Sun J; Jin C; Huang H
Cancer Lett; 2010 May; 291(2):177-86. PubMed ID: 19900757
[TBL] [Abstract][Full Text] [Related]
39. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.
Lai HK; Borden KL
Oncogene; 2000 Mar; 19(13):1623-34. PubMed ID: 10763819
[TBL] [Abstract][Full Text] [Related]
40. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus.
Muratani M; Gerlich D; Janicki SM; Gebhard M; Eils R; Spector DL
Nat Cell Biol; 2002 Feb; 4(2):106-10. PubMed ID: 11753375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
